Can-Fite BioPharma Ltd. Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Finance (Income) (Tables)

12 Months Ended

Dec. 31, 2017

	Year ended December 31,
	2017			2016			2015
	NIS in thousands
Finance expenses:

Bank commissions		102			105			76
Issuance expenses related to warrants exercisable into shares		1,132			-			2,116
Net loss from exchange rate fluctuations		2,572			580			-
Financial expenses from defined benefit plans		-			-			11
Other loss from long-term investment revaluation		16			-			-

		3,822			685			2,203
Finance income:

Interest income on bank deposits		(249	)		(342	)		(87	)
Net gain from exchange rate fluctuations		-			-			(492	)
Net change in fair value warrants exercisable into shares		(10,148	)		(6,657	)		(6,913	)

		(10,397	)		(6,999	)		(7,492	)